Early detection of bowel Cancer in the UK represents success of screening program
Bowel cancer, also known as colorectal cancer, is the second most lethal cancer after lung cancer, with the highest incidence …
Post
-
-
Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics
Eli Lilly has added yet another string to its M&A bow of 2026 after agreeing to acquire cancer specialist Ajax …
-
Pharma Meets AI Conference 2026: AI in pharma begins delivering measurable ROI
At the Pharma Meets AI conference in Barcelona, Spain, in April 2026, discussions around AI governance highlighted a growing shift …
-
Pharma Meets AI Conference 2026: AI governance shifts to embedded practice
At the Pharma Meets AI conference in Barcelona, Spain, in April 2026, discussions around AI governance highlighted a clear shift …
-
ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference, Phase III data for Aicuris’s pritelivir, …
-
ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference, Phase III data for Aicuris’s pritelivir, …
-
MFN changing the rules of the game for the Nordic countries
Innovative pharmaceutical trade associations across the Nordic region have reacted with vigilance to a recent report by GlobalData that highlighted …
-
Novartis secures pair of regulatory wins for skin disease and malaria treatments
Novartis has netted a pair of regulatory wins, winning European approval for an oral therapy in chronic spontaneous urticaria (CSU) …
-
UK biotech could be bound for recovery, BIA report reveals
New data debuted by the UK’s BioIndustry Association (BIA) has hinted towards the recovery of the British biotech financing market, …
-
Sun Pharma to acquire Organon for $11.75bn
Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash, …
-
The slow march of clinical biomarkers to become surrogate endpoints
Clinicians have often pushed for certain biomarkers to move from serving a purely informative role in clinical trials to becoming …
-
AAN 2026: Tavapadon post-hoc analysis strengthens its D1/D5 agonist pitch
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, AbbVie presented new results from its post-hoc analysis …
-
AAN 2026: Head-to-head trial shows superiority of Qulipta for migraine prevention
Historically, migraine prevention has been managed with a wide variety of non-migraine-specific drug classes, such as beta-adrenergic receptor blockers, calcium …
-
Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
On 20 April 2026, Biogen announced that it would acquire exclusive rights to TJ Biopharma’s anti-CD38 immunotherapy, felzartamab, in the …
-
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings
The European drug market could soon be poised to receive three new entries, as the European Committee for Healthcare and …
